serlopitant
Small moleculeexperimental
Serlopitant (INN, codenamed VPD-737) is a drug which acts as an NK1 receptor antagonist. It was assessed in clinical trials for the treatment of urinary incontinence and overactive bladder, but while it was superior to placebo it provided no advantage over existing approved drugs, and was not approved for further development for this indication. Serlopitant is now undergoing clinical trials for the treatment of chronic pruritus (itch) — Wikipedia
Clinical trial activity
14 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
14
Phase 3
3
Phase 4
0
Earliest trial started Feb 1, 2006 (NCT00290563)
Timeline
Indications
Mechanism of action
- Neurokinin 1 receptorANTAGONIST
TACR1 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H](O[C@H]1CC[C@@H]2CN(C3=CC(=O)CC3)C[C@H]2[C@@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1- Mol. weight
- 555.53 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSerlopitant ↗
- ChEMBLCHEMBL447955 ↗
Also known as
- mk0594
- serlopitant
- serlopitant
- serlopitant
- serlopitant
- vpd-737
- vpd-737
- vpd-737
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03836001 | Phase 2 | Apr 18, 2019 | Epidermolysis Bullosa Research Partnership, Stanford University, Vyne Therapeutics Inc. |
| NCT03841331 | Phase 2 | Jan 22, 2019 | Vyne Therapeutics Inc. |
| NCT03677401 | Phase 3 | Aug 29, 2018 | Medical University of Graz, University of Munster, Vyne Therapeutics Inc. |
| NCT03546816 | Phase 3 | May 2, 2018 | Vyne Therapeutics Inc. |
| NCT03540160 | Phase 3 | Mar 15, 2018 | Vyne Therapeutics Inc. |
| NCT03343639 | Phase 2 | Nov 1, 2017 | Vyne Therapeutics Inc. |
| NCT03282591 | Phase 2 | Oct 3, 2017 | University of Manchester, Vyne Therapeutics Inc. |
| NCT02975206 | Phase 2 | Nov 1, 2016 | Vyne Therapeutics Inc. |
| NCT02975271 | Phase 2 | Nov 1, 2016 | Vyne Therapeutics Inc. |
| NCT02654483 | Phase 2 | Jul 1, 2016 | Epidermolysis Bullosa Research Partnership, Stanford University, Vyne Therapeutics Inc. |
| NCT02196324 | Phase 2 | Jul 1, 2014 | University of Munster, Vyne Therapeutics Inc. |
| NCT01951274 | Phase 2 | Oct 1, 2013 | Vyne Therapeutics Inc. |
| NCT00835718 | Phase 2 | Feb 1, 2009 | Merck |
| NCT00290563 | Phase 2 | Feb 1, 2006 | Merck |
Showing 14 of 14 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vyne Therapeutics Inc. | For profit | 12 | 10 | 2 | 2013 |
| Epidermolysis Bullosa Research Partnership | Academic/Hospital | 2 | 0 | 1 | 2016 |
| Merck | For profit | 2 | 2 | 1 | 2006 |
| Stanford University | Academic/Hospital | 2 | 2 | 1 | 2016 |
| University of Munster | Academic/Hospital | 2 | 0 | 2 | 2014 |
| Medical University of Graz | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Manchester | Academic/Hospital | 1 | 0 | 1 | 2017 |
7 organizations
Page 1 / 1